Valuation: 3SBio Inc.

Capitalization 54.09B 61.19B 7.83B 6.58B 6B 5.73B 10.6B 709B 11.07B 69.62B 27.74B 342B 29.36B 28.75B 1,207B P/E ratio 2025 *
5.53x
P/E ratio 2026 * 16.3x
Enterprise value 44.3B 50.11B 6.41B 5.39B 4.91B 4.69B 8.68B 581B 9.07B 57.01B 22.71B 280B 24.05B 23.55B 989B EV / Sales 2025 *
2.4x
EV / Sales 2026 * 3.58x
Free-Float
72.15%
Yield 2025 *
3.66%
Yield 2026 * 2.29%
1 day-1.31%
1 week+2.98%
Current month+3.78%
1 month-10.77%
3 months-17.14%
6 months-20.67%
1 week 22.32
Extreme 22.32
24.74
1 month 22.3
Extreme 22.3
29.3
Current year 22.3
Extreme 22.3
29.3
1 year 6.24
Extreme 6.24
36.8
3 years 4.91
Extreme 4.91
36.8
5 years 4.72
Extreme 4.72
36.8
10 years 4.72
Extreme 4.72
36.8
Manager TitleAgeSince
Chief Executive Officer 63 01/01/2006
Director of Finance/CFO - 03/07/2023
Corporate Officer/Principal 56 27/11/2014
Director TitleAgeSince
Chairman 63 03/04/2012
Director/Board Member 56 11/06/2012
Director/Board Member 57 01/06/2015
Change 5d. change 1-year change 3-years change Capi.($)
-1.14%+2.98%+280.79%+186.49% 7.83B
-3.25%-0.56%+9.35%-0.36% 77.47B
-4.64%-10.05%-36.39%-46.41% 58.42B
-0.49%+1.53%+38.60%+235.19% 59.92B
+0.94%+71.00%+71.00%+71.00% 54.39B
-2.49%+6.92%+32.59%-33.99% 27.74B
-8.24%-0.86%+46.49%+26.23% 19.64B
+1.00%+12.28%+152.23%+109.61% 19.9B
+0.11%-0.49%+31.77%-75.19% 16.41B
+1.01%+12.05%+24.55%+63.58% 15.54B
Average -1.74%+4.19%+65.10%+53.62% 35.72B
Weighted average by Cap. -1.97%+1.49%+35.60%+50.89%

Financials

2025 *2026 *
Net sales 18.44B 20.86B 2.67B 2.24B 2.04B 1.95B 3.61B 242B 3.77B 23.74B 9.46B 116B 10.01B 9.8B 412B 11.49B 13B 1.66B 1.4B 1.27B 1.22B 2.25B 151B 2.35B 14.78B 5.89B 72.53B 6.24B 6.11B 256B
Net income 9.59B 10.85B 1.39B 1.17B 1.06B 1.01B 1.88B 126B 1.96B 12.34B 4.92B 60.53B 5.2B 5.1B 214B 3.26B 3.69B 472M 397M 362M 345M 639M 42.74B 667M 4.2B 1.67B 20.59B 1.77B 1.73B 72.77B
Net Debt -9.79B -11.08B -1.42B -1.19B -1.09B -1.04B -1.92B -128B -2B -12.6B -5.02B -61.83B -5.32B -5.21B -219B -12.98B -14.68B -1.88B -1.58B -1.44B -1.37B -2.54B -170B -2.66B -16.71B -6.66B -81.96B -7.05B -6.9B -290B
Logo 3SBio Inc.
3SBio Inc is an investment holding company mainly engaged in the development, production, marketing and sale of pharmaceutical products. The Company’s core products include several biopharmaceutical drugs, TPIAO, recombinant human erythropoietin(rhEPO) products, with brand of EPIAO and SEPO, Yisaipu, Cipterbin and a small molecule drug, Mandi and tumor necrosis factor (TNF). Through its subsidiaries, the Company is engaged in project management and consultation. The Company still engages in developing innovative biological products, including mAbs, bi-specific antibodies and fusion proteins, and a number of small molecule drugs, both innovative and generic, in the areas of nephrology, oncology, auto-immune and inflammatory diseases, ophthalmology and dermatological diseases. The Company distributes its products within the domestic market and to overseas markets.
Employees
6,268
Date Price Change Volume
11/02/26 24.22 $ -1.14% 8,003,610
10/02/26 24.50 $ +4.26% 24,013,480
09/02/26 23.50 $ +2.44% 9,099,428
06/02/26 22.94 $ -0.78% 12,237,060
05/02/26 23.12 $ -1.53% 22,253,930
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
21.66CNY
Average target price
34.72CNY
Spread / Average Target
+60.29%

Quarterly revenue - Rate of surprise